SCHEMBL3139767

SCHEMBL3139767

CC(C)(C)c1ccc([S+](c2ccccc2)c2ccc(C(C)(C)C)cc2)cc1.O=S(=O)([O-])C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.38
ALDH1A1 P00352 4/20 0.35
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
RORA P35398 1/20 0.34
HSD17B3 P37058 1/20 0.33
UQCRB P14927 1/20 0.33
HSD17B2 P37059 1/20 0.33
NPC1 O15118 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
MAOA P21397 1/20 0.32
NR1H2 P55055 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384049 1.00 HSD11B1 (0.38) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL3135852 0.99 HSD11B1 (0.37) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL384930 0.99 HSD11B1 (0.37) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL3137398 0.99 HSD11B1 (0.37) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL3135784 0.99 HSD11B1 (0.37) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL2438820 0.96 HSD11B1 (0.38) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL51945 0.94 ALDH1A1 (0.39) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL678361 0.93 ALDH1A1 (0.38) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL2435494 0.93 HSD11B1 (0.38) HSD11B1ALDH1A1CA1CA2RORA
SCHEMBL1593144 0.90 ALDH1A1 (0.40) HSD11B1ALDH1A1CA1CA2RORA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1676835-B1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT WAKO PURE CHEM IND LTD (JP) 2014-12-10 EP disclosed
US-7642368-B2 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-05 US disclosed
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2007-04-12 US disclosed
EP-1676835-A1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT Wako Pure Chemical Industries, Ltd. (JP) 2006-07-05 EP disclosed
US-6358665-B1 ONIUM SALT PRECURSOR FOR GENERATING FLUOROALKYLSULFONATE CLARIANT INTERNATIONAL LTD. (CH) 2002-03-19 US disclosed
EP-1033624-A1 RADIATION-SENSITIVE COMPOSITION OF CHEMICAL AMPLIFICATION TYPE Clariant International Ltd. (CH) 2000-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid ARSA, HAO2, HAO1 HSD11B1 718/4885ALDH1A1 139/4885CA1 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.